Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK-cell activity

Carter M. Suryadevara; Katherine A. Riccione; John H. Sampson

doi:10.1158/1078-0432.CCR-16-1666

Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK-cell activity

Carter M. Suryadevara
, Katherine A. Riccione
, John H. Sampson

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma.

Original language	English
Pages (from-to)	5164-5166
Number of pages	3
Journal	Clinical Cancer Research
Volume	22
Issue number	21
DOIs	https://doi.org/10.1158/1078-0432.CCR-16-1666
State	Published - 1 Nov 2016
Externally published	Yes

Access to Document

10.1158/1078-0432.CCR-16-1666

Cite this

@article{9093d2dafc0f43bb9986e6bd3de2caca,

title = "Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK-cell activity",

abstract = "Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma.",

author = "Suryadevara, \{Carter M.\} and Riccione, \{Katherine A.\} and Sampson, \{John H.\}",

note = "Publisher Copyright: {\textcopyright} 2016 AACR.",

year = "2016",

month = nov,

day = "1",

doi = "10.1158/1078-0432.CCR-16-1666",

language = "English",

volume = "22",

pages = "5164--5166",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "21",

}

TY - JOUR

T1 - Immunotherapy gone viral

T2 - Bortezomib and oHSV enhance antitumor NK-cell activity

AU - Suryadevara, Carter M.

AU - Riccione, Katherine A.

AU - Sampson, John H.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma.

AB - Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma.

UR - https://www.scopus.com/pages/publications/84994048433

U2 - 10.1158/1078-0432.CCR-16-1666

DO - 10.1158/1078-0432.CCR-16-1666

M3 - Article

C2 - 27521450

AN - SCOPUS:84994048433

SN - 1078-0432

VL - 22

SP - 5164

EP - 5166

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 21

ER -

Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK-cell activity

Abstract

Access to Document

Fingerprint

Cite this